Coya Therapeutics Successfully Engineers Regulatory T Cell Derived Exosomes With CTLA-4 Protein To Selectively Target Immune Cells With Potential To Deliver Targeted Therapies Across Multiple Diseases
Using proprietary exosome tethering modification technology, Treg derived exosomes were engineered with a surface protein, cytotoxic T lymphocyte associated protein 4 (CTLA-4) to increase selective targeting to immune